ASND
Ascendis Pharma A/s
$122.64
Earnings Summary
Revenue | $36Mn |
Net Profits | $-109.38Mn |
Net Profit Margins | -303.85% |
Highlights
Ascendis Pharma A/s’s revenue fell -24.04% since last year same period to $36Mn in the Q2 2024. On a quarterly growth basis, Ascendis Pharma A/s has generated 0% jump in its revenue since last 3-months.
Ascendis Pharma A/s’s net profit jumped 9.93% since last year same period to $-109.38Mn in the Q2 2024. On a quarterly growth basis, Ascendis Pharma A/s has generated 0% jump in its net profits since last 3-months.
Ascendis Pharma A/s’s net profit margin fell -18.59% since last year same period to -303.85% in the Q2 2024. On a quarterly growth basis, Ascendis Pharma A/s has generated 0% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Ascendis Pharma A/s post its latest quarter earnings
EPS Estimate Current Quarter | -1.89 |
EPS Estimate Current Year | -1.89 |
Highlights
Ascendis Pharma A/s’s earning per share (EPS) estimates for the current quarter stand at -1.89 - a -29.45% fall from last quarter’s estimates.
Ascendis Pharma A/s’s earning per share (EPS) estimates for the current year stand at -1.89.
Key Ratios
Key ratios of the Ascendis Pharma A/s post its Q3 2024 earnings
Earning Per Share (EPS) | -1.72 |
Highlights
Ascendis Pharma A/s’s earning per share (EPS) jumped 40.28% since last year same period to -1.72 in the Q3 2024. This indicates that the Ascendis Pharma A/s has generated 40.28% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2024-05-02 | -1.5 | -2.3 | -53.33% |
2024-11-05 | -1.89 | -1.72 | 8.99% |
₹0 US Stocks a/c Opening Fee